InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib [Yahoo! Finance]
LowReport
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib [Yahoo! Finance]
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
MediumReport
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.
MediumReport
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: